Botulinum toxin A liquid - Eirion Therapeutics
Alternative Names: AI-09Latest Information Update: 09 Oct 2024
At a glance
- Originator Anterios
- Developer AbbVie; Eirion Therapeutics
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glabellar lines
- Discontinued Acne; Facial wrinkles; Hyperhidrosis
Most Recent Events
- 01 Oct 2024 Efficacy and adverse events data from phase-I/II trial in Glabellar Lines released by Eirion Therapeutics
- 01 May 2024 Eirion Therapeutics completes a phase-I/II trial in Glabellar lines in USA (IM, Liquid) (NCT05565950)
- 03 Oct 2022 Phase-I/II clinical trials in Glabellar lines in USA (IM, Liquid) (NCT05565950)